Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells.

Authors: Gu, Shiyan; Lai, Yanhao; Chen, Hongyu; Liu, Yuan; Zhang, Zunzhen

Published In Sci Rep, (2017 09 22)

Abstract: Arsenic trioxide (ATO) resistance is a challenging problem in chemotherapy. However, the underlying mechanisms remain to be elucidated. In this study, we identified a high level of expression of miR-155 in a human lung adenocarcinoma A549R cell line that is highly resistant to ATO. We showed that the high level of miR-155 was associated with increased levels of cell survival, colony formation, cell migration and decreased cellular apoptosis, and this was mediated by high levels of Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1) and a high ratio of Bcl-2/Bax. Overexpression of the miR-155 mimic in A549R cells resulted in increased levels of colony formation and cell migration as well as reduced apoptosis along with increased Nrf2, NQO1 and HO-1. In contrast, silencing of miR-155 expression with its inhibitor in the cells, significantly decreased the cellular levels of Nrf2, NQO1 and HO-1 as well as the ratio of Bcl-2/Bax. This subsequently reduced the level of colony formation and cell migration facilitating ATO-induced apoptosis. Our results indicate that miR-155 mediated ATO resistance by upregulating the Nrf2 signaling pathway, but downregulating cellular apoptosis in lung cancer cells. Our study provides new insights into miR-155-mediated ATO resistance in lung cancer cells.

PubMed ID: 28939896 Exiting the NIEHS site

MeSH Terms: Adenocarcinoma of Lung/drug therapy*; Adenocarcinoma of Lung/genetics; Adenocarcinoma of Lung/metabolism; Antineoplastic Agents/pharmacology*; Apoptosis/drug effects; Arsenic Trioxide/pharmacology*; Cell Line, Tumor; Drug Resistance, Neoplasm*; Humans; Lung Neoplasms/drug therapy*; Lung Neoplasms/genetics; Lung Neoplasms/metabolism; MicroRNAs/genetics*; MicroRNAs/metabolism; NF-E2-Related Factor 2/genetics*; NF-E2-Related Factor 2/metabolism; Signal Transduction/drug effects

Back
to Top